Ranbaxy’s CEO stepping down and appointments at Avid, the USP and Novavax – People on the move
Atul Sobti has stepped down as CEO and managing director of Ranbaxy Laboratories. Sobti joined Ranbaxy in 2007 and was made CEO in May 2009. Arun Sawhney, the president of Ranbaxy’s global pharma business, is replacing Sobti as managing director.
Avid Radiopharmaceuticals has named Mark Mintun as chief medical officer. Before filling the newly created position Mintun worked at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis, Missouri, US.
Amy Karren, director of scientific development at Nelson Laboratories, has been elected to serve a five-year term on the US Pharmacopeia Convention (USP) small molecules monographs 1 committee.
The International AIDS Vaccine Initiative (IAVI) has appointed Michael Caulfield as executive director of its vaccine design and development laboratory. Caulfield spent the past 16 years at Merck & Co and before that worked as a researcher at the Cleveland Clinic.
Richard Douglas has been elected to the board of directors at Novavax. Douglas is currently SVP, corporate development at Genzyme and previously worked at Integrated Genetics.
KV Pharmaceutical has named Robert Baldini as an independent member of its board of directors. Baldini has worked in the pharma industry for 50 years at companies including Pfizer, Geigy, Key Pharmaceuticals and Kos Pharmaceuticals.
Craig Eagle has joined the scientific advisory board at Generex Biotechnology. Eagle is the current VP of strategic alliances and partnerships at Pfizer’s oncology unit.
Oxis International has appointed John Repine to its scientific advisory board. Repine is the director of the Webb-Waring Center for Oxidative Stress Research at the University of Denver Colorado Health Sciences Center.
Ian Weatherhead has been named as director of communications for Sanofi-Aventis UK. Weatherhead joins from UCB and earlier in his career worked at AstraZeneca and Syngenta.
Pinnacle Biologics has elected James Foght to its board of directors. Foght was a co-founder of DuPont Pharmaceuticals, founder of Vector Securities International and holds a number of advisory positions.
